PMID: 7010546Jan 1, 1980Paper

Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics

Scandinavian Journal of Infectious Diseases. Supplementum
P HenrikssonK Haeger

Abstract

49 newborns and infants were treated with netilmicin for verified or suspected infections. Infection was verified in 23 patients (mean gestational age 32 weeks and mean body weight 2100 g) and clinical cure or marked improvement occurred in 20 of these. Of the remaining 3 patients, 2 died, partly due to reasons unassociated with infection. 25 causative organisms were isolated and bacteriological elimination was achieved in 73% of the cases. At an average dose of 2.6 mg/kg twice a day, peak serum concentrations (30 min following injection) were 7.4 +/- 3.4 micrograms/ml. Serum half life was approximately 4.5 hours for infants born at term, and longer at shorter gestational age. Netilmicin is considered a safe and efficient aminoglycoside with a low rate of adverse effects.

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Scandinavian Journal of Infectious Diseases. Supplementum
H MichalsenT Bergan
Scandinavian Journal of Infectious Diseases. Supplementum
P O MadsenP G Welling
Scandinavian Journal of Infectious Diseases. Supplementum
B PeitersenA Friis-Møller
© 2021 Meta ULC. All rights reserved